EYLEA® (aflibercept) 8 mg
Retinal vein occlusion (RVO)
PERFORMANCE YOU CAN TRUST
Give your
- Mean CRT reductions in the EYLEA 8 mg 8q8/3 arm (QUASAR) were -342.5 µm 4 weeks after 1 dose and reduction was maintained through to Week 64.
EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to macular oedema secondary to retinal vein occlusion (branch, central and hemiretinal RVO).
EYLEA 8 mg offers a flexible posology with Q4 to Q20 dosing in RVO with only 3 loading doses.[1]
A 34% slower ocular clearance rate, can result in 6 weeks longer VEGF suppression than EYLEA 2 mg†
Mean CRT reductions with EYLEA 8 mg in 8q8/3 was -342.5 µm 4 weeks after 1 dose and -361 µm from baseline to Week 64
Vision gains were sustained through Week 64 with ~3 fewer injections (p<0.0001)§¶ with ~9 in 10 patients achieving last assigned interval of ≥3 months in the 8Q8/3 treatment arm‖
*QUASAR was a multicentre, double-masked study in patients with treatment-naïve macular oedema secondary to RVO. Patients were randomised to receive EYLEA 2Q4 (n=301), EYLEA 8Q8/3 (n=293) or EYLEA 8Q8/5 (n=298). Further information about the QUASAR study can be found further down the page.
†The impact of molecular properties on clinical outcomes is yet to be defined. Suppression is based on a PK/PD model. This is a hypothetical illustrative model based on in vitro data and should be interpreted with caution.
‡CRT reduction was observed 4 weeks after the first loading dose with EYLEA 8 mg.
§Key secondary endpoint.
¶Vision gains were achieved across BRVO and CRVO/HRVO types.
‖In QUASAR, patients in the 8Q8/3 and 8Q8/5 groups had 3 and 5 initial monthly injections, respectively, before being extended to Q8 intervals, with the opportunity for extension or shortening based on DRM criteria.
In the video above (9 minutes),
Prescribing information for EYLEA® (aflibercept)
QUASAR
Deliver vision gains, sustained with fewer injections vs EYLEA 2 mg
Mean of ~3 fewer injections required over 64 weeks with EYLEA 8 mg vs EYLEA 2 mg (27% reduction, 8.5 vs 11.7, p<0.0001)*
QUASAR primary endpoint (non-inferior vision gains at week 36) met:
- 17.4 letters average gain from baseline at Week 36 with EYLEA 8 mg vs 17.5 with EYLEA 2 mg (p<0.0001)†‡§
EYLEA 8 mg improved vision from baseline regardless of RVO subtype (BRVO or CRVO/HRVO).
*With a two-sided inferiority test.
†Vision gains were for the 8Q8/3 arm and this posology is consistent with the SmPC.
‡One-sided non-inferiority.
§EYLEA 8 mg improved vision from baseline regardless of RVO subtype (BRVO or CRVO/HRVO).
¶Missing endpoint values imputed using a multiple imputation procedure. Estimates based on a linear regression model, within the multiple imputation procedure, adjusted for BL BCVA, BL CRT and stratification variables (geographic region [Japan vs Asia-Pacific vs Europe vs America], BCVA score [>60 vs ≥60], RVO type [CRVO/HRVO vs BRVO]).
2Q4, aflibercept 2 mg administered every 4 weeks; 2Q8, aflibercept 2 mg administered every 8 weeks; 8Q8/3, aflibercept 8 mg administered every 8 weeks, after 3 monthly injections at 4-week intervals; 8Q8/5, aflibercept 8 mg administered every 8 weeks, after 5 monthly injections at 4-week intervals; 8Q12, aflibercept 8 mg administered every 12 weeks; 8Q16, aflibercept 8 mg administered every 16 weeks; AE, adverse event; APTC, AntiPlatelet Trialists’ Collaboration; BCVA, best-corrected visual acuity; BL, baseline; BRVO, branch retinal vein occlusion; CRT, central retinal thickness; CRVO, central retinal vein occlusion; DMO, diabetic macular oedema; DRM, dose regimen modification; ETDRS, Early Treatment Diabetic Retinopathy Study; FAS, full analysis set; HRVO, hemi-retinal vein occlusion; IOI, intraocular inflammation; LS, least squares; MoA, mechanism of action; nAMD, neovascular age-related macular degeneration; RVO, retinal vein occlusion; SAE, serious adverse event; SAF, safety analysis set; SD, standard deviation; SD-OCT, spectral-domain optical coherence tomography; T&E, treat and extend; TEAE, treatment-emergent adverse event; Wk, week.
PP-EYL-GB-3077 | February 2026